Filing Flows

Filing Flows › Teva Pharmaceutical Industries (TEVA) › Q1 2026

Teva Pharmaceutical Industries (TEVA) Q1 2026 earnings results (first quarter 2026)

10-Q filed Apr 29, 2026

Teva Pharmaceutical Industries (TEVA) reported revenue of $4.0B for the first quarter 2026 (Q1 2026), +2% from a year earlier and -15% from the quarter before. Operating margin was 16.4%, net earnings $369M (9.3% of revenue).

Revenue$4.0B
Year over year+2%
Quarter over quarter-15%
Operating margin16.4%
Net earnings$369M

Teva Pharmaceutical Industries, Q1 2026: revenue $4.0B (+2% year over year), operating margin 16.4%, net earnings $369M, operating cash flow −$40.0M. The chart follows the revenue to costs, profit and cash.

Q1 2026AmountQ/QY/Y
Revenue$4.0B-15%+2%
Gross profit$2.0B-26%+5%
Operating profit$652M+117%+26%
Net earnings$369M-23%+68%
Operating cash flow−$40.0M-103%—

What changed

Revenue was $4.0B in Q1 2026, up 2% year over year and down 15% from the previous quarter. Product was the largest line at 85% of revenue. Product and Service Other added $0.08B year over year (up 107%), 89% of the total change.

Gross margin was 49.5%, up 1.3 points from Q1 2025. Operating profit was $0.65B, a 16.4% margin (up 3.0 points year over year). Of the extra revenue versus Q1 2025, 146% reached operating profit, above the 13% margin then. Operating expenses fell 3% while revenue rose 2%. The fastest-growing cost line was Sales & marketing (+12%). Net earnings were $0.37B, up 72% year over year. The effective tax rate was 15.3%.

Operating cash flow was −$0.04B. Non-cash charges added back $0.24B of depreciation and amortization and $0.04B of share-based compensation. Working capital and other items used $0.69B. Capital expenditures of $0.17B exceeded it, leaving free cash flow of −$0.21B.

Questions

What was Teva Pharmaceutical Industries' revenue in the first quarter 2026?

Teva Pharmaceutical Industries (TEVA) reported revenue of $4.0B for the first quarter 2026 (Q1 2026), +2% from a year earlier and -15% from the quarter before.

Was Teva Pharmaceutical Industries profitable in the first quarter 2026?

Operating profit was $652M (16.4% of revenue) and net earnings $369M.

Open the interactive Sankey →

Source: Teva Pharmaceutical Industries 10-Q on SEC EDGAR.